Of the 1271 cases assessed, those with nuclear BQ overexpression showed statistically significant association with poorer survival outcome and tamoxifen resistance, demonstrating that nuclear BQ expression in primary breast cancer could be a robust biomarker for predicting tamoxifen resistance in ER+ breast cancer [25]. The gene discussed is ESR1; the disease is breast cancer.